Kim J H, Durack D T
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Am J Med. 1988 May;84(5):919-28. doi: 10.1016/0002-9343(88)90072-1.
HTLV-I, the first human oncovirus, is a type C retrovirus linked to the development of ATLL. The virus shows a striking ethnogeographic distribution that is only partially understood. Certain populations at high risk for AIDS appear to have a higher incidence of HTLV-I infection. The extended latent period renders present knowledge of the sequelae and natural history of HTLV-I seropositivity incomplete, although recent data suggest that HTLV-I infection may have important implications for blood transfusion, organ transfer, and public health policy. A variety of clinical syndromes have been associated with infection, ranging from an asymptomatic carrier state to acute ATLL with lymphadenopathy, hepatosplenomegaly, hypercalcemia, cutaneous lesions, and systemic immunosuppression. Conventional chemotherapy is marginally effective; innovative approaches to therapy are presently being evaluated.
人类嗜T淋巴细胞病毒I型（HTLV-I）是第一种人类致癌病毒，是一种与成人T细胞白血病淋巴瘤（ATLL）发生相关的C型逆转录病毒。该病毒呈现出显著的种族地理分布，但人们对此仅了解一部分。某些艾滋病高危人群似乎HTLV-I感染发生率更高。尽管最近的数据表明HTLV-I感染可能对输血、器官移植和公共卫生政策有重要影响，但由于其较长的潜伏期，目前关于HTLV-I血清阳性的后遗症和自然史的知识并不完整。多种临床综合征与感染有关，从无症状携带状态到伴有淋巴结病、肝脾肿大、高钙血症、皮肤病变和全身免疫抑制的急性ATLL。传统化疗效果甚微；目前正在评估创新的治疗方法。
